Afficher la notice abrégée

Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019

dc.rights.licenseopenen_US
dc.contributor.authorVAN SANTEN, Daniela K.
dc.contributor.authorSACKS-DAVIS, Rachel
dc.contributor.authorSTEWART, Ashleigh
dc.contributor.authorBOYD, Anders
dc.contributor.authorYOUNG, Jim
dc.contributor.authorVAN DER VALK, Marc
dc.contributor.authorSMIT, Colette
dc.contributor.authorRAUCH, Andri
dc.contributor.authorBRAUN, Dominique L.
dc.contributor.authorJARRIN, Inmaculada
dc.contributor.authorBERENGUER, Juan
dc.contributor.authorLAZARUS, Jeffrey V.
dc.contributor.authorLACOMBE, Karine
dc.contributor.authorREQUENA, Maria-Bernarda
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorLELEUX, Olivier
dc.contributor.authorSALMON, Dominique
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorMATTHEWS, Gail
dc.contributor.authorDOYLE, Joseph S.
dc.contributor.authorSPELMAN, Tim
dc.contributor.authorKLEIN, Marina B.
dc.contributor.authorPRINS, Maria
dc.contributor.authorASSELIN, Jason
dc.contributor.authorSTOOVE, Mark A.
dc.contributor.authorHELLARD, Margaret
dc.date.accessioned2023-03-20T10:17:28Z
dc.date.available2023-03-20T10:17:28Z
dc.date.issued2023-02
dc.identifier.issn2589-5370en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172377
dc.description.abstractEnBACKGROUND: Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV) incidence through a "treatment as prevention" (TasP) effect. We assessed changes in primary HCV incidence following DAA access among people living with HIV (PLHIV). METHODS: We used pooled individual-level data from six cohorts from the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC). Follow-up started from the first recorded negative HCV antibody test date and ended at last negative antibody test or estimated infection date. Follow-up was restricted to 2010-2019. We used segmented Poisson regression to model trends across pre-, limited- (i.e., restrictions on access) and broad-DAA access periods. FINDINGS: Overall, 45,942 participants had at least one HCV antibody negative result and follow-up between 2010 and 2019. We observed 2042 incident HCV infections over 248,189 person-years (PY). Pooled incidence decreased from 0.91 per 100 PY in 2015 to 0.41 per 100 PY in 2019. Compared to the average pre-DAA period incidence (0.90 per 100 PY), average incidence was similar during the limited-DAA access period (Incidence rate ratio [IRR] = 0.98; 95%CI = 0.87, 1.11), and 52% lower during the broad-DAA access period (IRR = 0.48; 95%CI = 0.42, 0.52). The average annual decline in HCV incidence was 2% in the pre-DAA period; an additional 9% annual decline in incidence was observed during the limited-DAA access period (IRR = 0.91; 95%CI = 0.82, 1.00) and a further 20% decline in the broad-DAA access period (IRR = 0.80, 95%CI = 0.73, 0.89). INTERPRETATION: Our findings suggest that broad DAA access has a TasP effect on primary HCV incidence among PLHIV. Based on the initial years of DAA availability, the countries in the InCHEHC collaboration are on track to meet the World Health Organization's 80% HCV incidence reduction target for PLHIV by 2030. FUNDING: This study was funded by the Australian Government National Health and Medical Research Council (Grant number GNT1132902).
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enHIV
dc.subject.enHepatitis C virus
dc.subject.enElimination
dc.subject.enDirect-acting antivirals
dc.subject.enTrends
dc.subject.enIncidence
dc.title.enTreatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019
dc.title.alternativeEClinicalMedicineen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.eclinm.2022.101810en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36618902en_US
bordeaux.journalEClinicalMedicineen_US
bordeaux.page101810en_US
bordeaux.volume56en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=EClinicalMedicine&rft.date=2023-02&rft.volume=56&rft.spage=101810&rft.epage=101810&rft.eissn=2589-5370&rft.issn=2589-5370&rft.au=VAN%20SANTEN,%20Daniela%20K.&SACKS-DAVIS,%20Rachel&STEWART,%20Ashleigh&BOYD,%20Anders&YOUNG,%20Jim&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BPH_ECM_2023_VanSanten.pdf
Taille:
945.3Ko
Format:
PDF
Voir/Ouvrir
Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée